Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedAug 28, 2026
DataAggregated Company Financials
Companies63
  • 7D1.0%
  • 3M26.3%
  • 1Y27.8%
  • YTD10.5%

Over the last 7 days, the Life Sciences industry has risen 2.6%, driven by gains from Illumina of 6.8%. In the last 12 months, the industry was up 28%. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 28 Aug 2026US$747.0bUS$153.5bUS$14.2b41.7x52.5x4.9x
Sun, 26 Jul 2026US$658.7bUS$152.4bUS$14.0b41.4x47.2x4.3x
Tue, 23 Jun 2026US$576.2bUS$150.6bUS$13.8b40.5x41.8x3.8x
Thu, 21 May 2026US$533.3bUS$150.3bUS$14.0b33x38.1x3.5x
Sat, 18 Apr 2026US$584.6bUS$147.9bUS$14.1b38.3x41.5x4x
Mon, 16 Mar 2026US$536.3bUS$147.8bUS$14.0b34.3x38.3x3.6x
Wed, 11 Feb 2026US$616.5bUS$147.6bUS$12.9b34.1x47.9x4.2x
Fri, 09 Jan 2026US$700.8bUS$145.8bUS$12.4b37.2x56.7x4.8x
Sun, 07 Dec 2025US$662.3bUS$145.8bUS$12.5b35.7x53.1x4.5x
Tue, 04 Nov 2025US$648.1bUS$145.4bUS$12.0b33.6x53.8x4.5x
Thu, 02 Oct 2025US$579.5bUS$144.3bUS$14.6b32.2x39.8x4x
Sat, 30 Aug 2025US$581.8bUS$144.3bUS$14.6b29.2x40x4x
Mon, 28 Jul 2025US$585.5bUS$143.7bUS$8.8b40.1x66.5x4.1x
Wed, 25 Jun 2025US$527.6bUS$142.9bUS$9.2b35.9x57.5x3.7x
Fri, 23 May 2025US$498.1bUS$142.8bUS$9.1b32.1x54.8x3.5x
Sun, 20 Apr 2025US$504.0bUS$142.6bUS$10.0b34.3x50.6x3.5x
Tue, 18 Mar 2025US$597.8bUS$143.1bUS$9.8b39x61.2x4.2x
Thu, 13 Feb 2025US$633.3bUS$143.2bUS$11.2b35.6x56.6x4.4x
Sat, 11 Jan 2025US$677.6bUS$142.4bUS$10.2b43.2x66.4x4.8x
Mon, 09 Dec 2024US$664.3bUS$142.4bUS$10.2b44.2x65x4.7x
Wed, 06 Nov 2024US$691.4bUS$142.4bUS$10.4b42.7x66.6x4.9x
Fri, 04 Oct 2024US$744.1bUS$141.8bUS$8.5b38.3x87.6x5.2x
Sun, 01 Sep 2024US$749.5bUS$141.8bUS$8.5b37.8x88.2x5.3x
Tue, 30 Jul 2024US$732.9bUS$141.0bUS$12.6b37.1x58.3x5.2x
Thu, 27 Jun 2024US$686.9bUS$141.3bUS$12.2b37.9x56.4x4.9x
Sat, 25 May 2024US$725.1bUS$141.5bUS$12.4b38.7x58.3x5.1x
Mon, 22 Apr 2024US$682.2bUS$142.0bUS$12.8b40.8x53.3x4.8x
Wed, 20 Mar 2024US$746.6bUS$142.1bUS$12.8b44.7x58.2x5.3x
Fri, 16 Feb 2024US$722.2bUS$142.2bUS$13.0b43.4x55.5x5.1x
Sun, 14 Jan 2024US$684.9bUS$153.9bUS$14.2b35.4x48.3x4.5x
Tue, 12 Dec 2023US$652.7bUS$153.7bUS$14.0b35.4x46.6x4.2x
Thu, 09 Nov 2023US$597.3bUS$153.9bUS$11.0b30.9x54.1x3.9x
Sat, 07 Oct 2023US$644.8bUS$154.6bUS$11.2b33.1x57.6x4.2x
Mon, 04 Sep 2023US$735.8bUS$154.6bUS$11.2b33.1x65.7x4.8x
Price to Earnings Ratio

65.7x


Total Market Cap: US$735.8bTotal Earnings: US$11.2bTotal Revenue: US$154.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 55.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 52.5x which is lower than its 3-year average PE of 55.5x.
  • The 3-year average PS ratio of 4.4x is lower than the industry's current PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 8.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.16%
Healthcare-0.20%
Life Sciences1.05%
Clinical Research and Equipment1.05%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ILMN IlluminaUS$227.696.8%
+US$2.2b		129.6%PE41.7x
WAT WatersUS$421.264.1%
+US$1.6b		41.5%PE248.4x
TMO Thermo Fisher ScientificUS$630.700.5%
+US$1.2b		28.8%PE33.5x
IQV IQVIA HoldingsUS$262.382.5%
+US$1.0b		39.0%PE31.4x
TEM Tempus AIUS$70.696.1%
+US$729.0m		-4.0%PS8.9x

Latest News

QGEN
US$43.74
Qiagen
7D
-2.6%
1Y
-9.9%
A
US$157.69
Agilent Technologies
7D
0.9%
1Y
26.2%
DHR
US$215.68
Danaher
7D
-0.1%
1Y
5.1%
TMO
US$630.70
Thermo Fisher Scientific
7D
0.5%
1Y
28.8%
TEM
US$70.69
Tempus AI
7D
6.1%
1Y
-4.0%
MEDP
US$611.57
Medpace Holdings
7D
-0.2%
1Y
29.3%
New Narrative • Aug 25

Why Medpace Outperforms Competitors in the Mid-Sized Biotech Niche

Medpace Holdings is a clinical research organization, or CRO. The simplest way to understand a CRO is to think of it as a general contractor for clinical trials.
AZTA
US$33.61
Azenta
7D
-7.9%
1Y
12.3%
ILMN
US$227.69
Illumina
7D
6.8%
1Y
129.6%
Narrative Update • Aug 24

ILMN: Clinical Sequencing And Healthier Sector Spending Are Expected To Sustain A Balanced Outlook

Illumina's updated analyst price target moves to $230, supported by analysts citing stronger recent instrument placements, Q2 results that were generally viewed as solid, and expectations for healthier genomics and diagnostics spending over the coming years. Analyst Commentary Recent research on Illumina points to a more constructive tone from several bullish analysts who have raised price targets following Q2 results, updated guidance, and industry checks.
IQV
US$262.38
IQVIA Holdings
7D
2.5%
1Y
39.0%
Narrative Update • Aug 24

IQV: CRO Recovery And AI Strength Will Support Measured Earnings Reacceleration

The analyst fair value estimate for IQVIA Holdings has moved from $232 to about $275, with analysts tying higher price targets to stronger Q2 results, improving CRO demand, healthy commercial activity, and confidence in the company's technology position and execution. Analyst Commentary Recent Street research around IQVIA Holdings has turned more constructive, with a series of higher fair value targets following the Q2 earnings report.
WAT
US$421.26
Waters
7D
4.1%
1Y
41.5%
BIO
US$389.94
Bio-Rad Laboratories
7D
3.6%
1Y
32.8%
Narrative Update • Aug 20

BIO: Buybacks Will Likely Mask Flat Near‑Term Revenue Trend

Analysts have raised their price target on Bio-Rad Laboratories from $293 to $329, citing updated assumptions on revenue growth, profit margins, and future P/E levels that feed into their valuation models. What’s in the News for Bio-Rad Laboratories Bio-Rad Laboratories issued earnings guidance for the third quarter of 2026, indicating that revenue is expected to be flat compared with the second quarter.
RVTY
US$129.71
Revvity
7D
4.5%
1Y
45.4%
Narrative Update • Aug 20

RVTY: Elevated Multiple And Sector Headwinds Will Challenge 2026 Outlook

Analysts have lifted the fair value estimate for Revvity stock from $90 to $100, pointing to updated price targets in the $115 to $130 range and research that highlights steady sector trends, healthier capital spending, and a higher assumed future P/E multiple, despite more conservative profit margin assumptions. Analyst Commentary on Revvity Recent Street research on Revvity points to a mix of optimism and caution.
BRKR
US$59.25
Bruker
7D
-1.1%
1Y
77.1%
ICLR
US$169.72
ICON
7D
-2.6%
1Y
-3.0%
Narrative Update • Aug 15

ICLR: Bookings Momentum And Accounting Clarity Will Support Stronger 2027 Earnings Visibility

ICON's analyst price target has been revised higher, with fair value moving from $181.19 to $185.56 as analysts factor in stronger bookings, improved earnings visibility into 2027, and updated models following recent quarterly results and the resolution of accounting related questions. Analyst Commentary Recent Street research on ICON shows a wide range of views, with most analysts raising price targets while differing on how much risk remains around execution, margins, and longer term growth expectations.
ALMR
US$33.00
Alamar Biosciences
7D
-4.7%
1Y
n/a
Seeking Alpha • Aug 14

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Summary Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities. I remain bullish, despite premium valuation and execution risks, as consumables growth, margin expansion, and large-scale neuro collaborations underpin a compelling long-term thesis. Read the full article on Seeking Alpha
WST
US$346.09
West Pharmaceutical Services
7D
-2.2%
1Y
41.0%